No connection

Search Results

HITI vs TNXP

HITI
High Tide Inc.
BEARISH
Price
$2.33
Market Cap
$204.8M
Sector
Healthcare
AI Confidence
80%
TNXP
Tonix Pharmaceuticals Holding Corp.
BEARISH
Price
$14.34
Market Cap
$203.7M
Sector
Healthcare
AI Confidence
95%

Valuation

P/E Ratio
HITI
--
TNXP
--
Forward P/E
HITI
16.47
TNXP
-2.78
P/B Ratio
HITI
3.23
TNXP
0.75
P/S Ratio
HITI
0.33
TNXP
15.54
EV/EBITDA
HITI
10.1
TNXP
0.11

Profitability

Gross Margin
HITI
25.8%
TNXP
49.34%
Operating Margin
HITI
2.32%
TNXP
-895.84%
Profit Margin
HITI
-7.42%
TNXP
0.0%
ROE
HITI
-39.72%
TNXP
-64.48%
ROA
HITI
3.87%
TNXP
-35.71%

Growth

Revenue Growth
HITI
25.2%
TNXP
108.8%
Earnings Growth
HITI
--
TNXP
--

Financial Health

Debt/Equity
HITI
1.1
TNXP
0.01
Current Ratio
HITI
1.43
TNXP
7.42
Quick Ratio
HITI
0.49
TNXP
6.96

Dividends

Dividend Yield
HITI
--
TNXP
--
Payout Ratio
HITI
0.0%
TNXP
0.0%

AI Verdict

HITI BEARISH

HITI exhibits severe fundamental weakness, highlighted by a Piotroski F-Score of 2/9, indicating poor financial health and operational inefficiency. While the company shows strong top-line revenue growth of 25.20% and analysts maintain a 'strong_buy' rating with a target of $5.67, these are contradicted by a 0/100 technical trend and a negative profit margin of -7.42%. The disconnect between analyst optimism and the deterministic health scores suggests a high-risk speculative play rather than a value investment. The company's inability to convert revenue growth into consistent net income remains the primary concern.

Strengths
Strong YoY revenue growth of 25.20%
Positive operating margin of 2.32% suggesting core business viability
Very low Price/Sales ratio (0.33) indicating potential undervaluation of assets
Risks
Critical financial health (Piotroski F-Score 2/9)
Severe technical bearishness (Technical Trend 0/100)
Poor liquidity for immediate obligations (Quick Ratio 0.49)
TNXP BEARISH

TNXP exhibits severe financial distress, highlighted by a critical Piotroski F-Score of 1/9 and a catastrophic operating margin of -895.84%. While the company maintains a high current ratio (7.42) and low debt, these are likely the result of aggressive equity dilution rather than operational success, as evidenced by a -100% 5-year price return. Despite a 'strong_buy' analyst consensus and high revenue growth, the lack of earnings beats (0/4 in the last year) and a total collapse in long-term shareholder value indicate a high-risk profile. The disconnect between the analyst target price ($54.33) and the fundamental decay is extreme.

Strengths
Strong YoY revenue growth of 108.80%
High liquidity with a current ratio of 7.42
Very low debt-to-equity ratio (0.01)
Risks
Extreme operational inefficiency (Operating Margin -895.84%)
Critical financial health (Piotroski F-Score 1/9)
Consistent failure to meet earnings estimates (0/4 last 4 quarters)

Compare Another Pair

HITI vs TNXP: Head-to-Head Comparison

This page compares High Tide Inc. (HITI) and Tonix Pharmaceuticals Holding Corp. (TNXP) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile